In a resident with recurrent urinary tract infections, dementia, diabetes mellitus, chronic kidney disease stage 3b, and penicillin allergy who is on fosfomycin 3 g daily, and whose recent urine culture grew multidrug‑resistant Klebsiella (susceptible only to ertapenem and meropenem) and Proteus, should I reassess symptoms and, if symptomatic, repeat urinalysis, urine culture, complete blood count, and basic metabolic panel before deciding whether to discontinue or change therapy, given a prior serum creatinine of 1.28 mg/dL and estimated creatinine clearance of 39 mL/min?

Change Therapy Immediately to a Carbapenem

Given this patient's multidrug-resistant Klebsiella susceptible only to ertapenem/meropenem, you should switch from fosfomycin to ertapenem (or meropenem if penicillin allergy permits carbapenem use) now, and reassess symptoms with repeat UA/urine culture plus CBC/BMP to confirm clinical response and guide duration. Fosfomycin has insufficient evidence for treating complicated UTIs caused by MDR organisms, particularly when susceptibility is unknown 1.

Why Fosfomycin is Inadequate Here

This patient has a complicated UTI by definition—she has diabetes mellitus, CKD stage 3b, recurrent infections, and is in a healthcare setting (nursing home resident), all of which are recognized complicating factors 1. The 2024 EAU guidelines explicitly state that fosfomycin should be avoided for pyelonephritis and complicated UTIs due to insufficient efficacy data 1. The FDA label confirms fosfomycin is indicated only for uncomplicated cystitis in women 2, and while retrospective studies show some promise in MDR UTIs 3, these are low-quality evidence compared to guideline recommendations.

Critical issue: Fosfomycin susceptibility was not reported for the Klebsiella isolate. Without documented susceptibility, you're treating blindly with an agent that has questionable tissue penetration for complicated infections and no guideline support for this indication.

The Carbapenem Imperative

The 2024 EAU guidelines are unequivocal: carbapenems should be considered in patients with early culture results indicating multidrug-resistant organisms 1. Your patient's culture shows exactly this—MDR Klebsiella resistant to ciprofloxacin, nitrofurantoin, and Bactrim, with documented susceptibility only to ertapenem/meropenem.

Dosing Considerations with CKD 3b

With CrCl 39 mL/min, ertapenem requires dose adjustment:

• Ertapenem: 500 mg IV once daily (reduced from standard 1 g) for CrCl 30-50 mL/min 4
• Monitor renal function closely as fosfomycin's half-life increases dramatically in renal impairment (from 5.7 hours to 50 hours in severe CKD) 2

Penicillin Allergy Caveat

Verify the nature of the penicillin allergy. If it's a true IgE-mediated reaction (anaphylaxis, angioedema), carbapenem cross-reactivity risk is approximately 1-2%. Most "penicillin allergies" are not true allergies, and carbapenems can be used safely. If the allergy is severe and documented, consider infectious disease consultation for desensitization or alternative agents, though options are extremely limited given the resistance pattern.

Reassessment Strategy

Before switching therapy, obtain:

1. Symptom assessment using the geriatric UTI algorithm 5:

   • Look for recent-onset dysuria, frequency, urgency, or costovertebral angle tenderness
   • In dementia patients, assess for clear-cut delirium (acute change in attention/awareness over hours to days, fluctuating severity)
   • Do not rely on nonspecific symptoms like cloudy urine, odor changes, or isolated mental status changes without delirium—these do not indicate UTI in elderly patients 5

2. Repeat UA/urine culture: Essential to document persistent infection versus asymptomatic bacteriuria. The negative dipstick (nitrite AND leukocyte esterase both negative) would argue against active UTI 5, but given MDR organisms and resistant Enterobacteriaceae, inflammatory markers may be attenuated 6

3. CBC/BMP:

   • Check WBC for systemic response
   • Critical: Monitor creatinine and electrolytes given CKD 3b and potential fosfomycin-induced electrolyte disturbances (hypokalemia, hypernatremia) 2
   • Fosfomycin can cause agranulocytosis in CKD patients 7—check absolute neutrophil count

Treatment Duration

For complicated UTI with MDR organisms in a patient with diabetes and CKD, plan for 14 days of carbapenem therapy 1. The guidelines recommend 7-14 days, with 14 days preferred when prostatitis cannot be excluded (less relevant here) or in patients with significant comorbidities like diabetes 1.

Common Pitfalls to Avoid

• Don't continue fosfomycin hoping for the best: The organism's susceptibility is unknown, and guidelines don't support this approach for complicated UTI
• Don't wait for symptom resolution to reassess: With dementia, symptom reporting is unreliable; objective markers (culture, labs) are essential
• Don't assume asymptomatic bacteriuria: Recurrent UTIs in this population often present atypically; the MDR organism and multiple comorbidities warrant treatment
• Don't forget to check for obstruction: With recurrent UTIs and CKD, obtain renal ultrasound if not recently done to rule out structural abnormalities 1

The Proteus co-infection is also concerning—Proteus is associated with struvite stones and upper tract involvement. If symptoms persist despite appropriate therapy, imaging is mandatory 1.